大剂量甲氨喋呤联合利妥昔单克隆抗体治疗原发性中枢神经系统淋巴瘤的疗效观察
发布时间：2018-08-12 07:42
【摘要】：目的:探讨大剂量甲氨喋呤联合利妥昔单克隆抗体治疗原发性中枢神经系统淋巴瘤(PCNSL)的疗效。方法:选取我科收治的100例原发性中枢神经系统淋巴瘤患者并将他们分为靶向治疗组和传统治疗组,各组50例。靶向治疗组所采用的治疗方法为大剂量甲氨喋呤联合利妥昔单克隆抗体治疗,传统治疗组所采用的治疗方法为传统的大剂量甲氨喋呤与全脑放疗相结合治疗,进行相关的影像学检查,统计两组的一般临床资料、影像学资料、随访结果以及生存时间并进行比较与分析。结果:在靶向治疗组中,完全缓解的病例有33例,病情稳定的病例有9例,部分缓解的有5例,病情有进展的有3例;而在传统治疗组中,完全缓解的病例有29例,病情稳定的病例有5例,部分缓解的有11例,病情进展的有5例。靶向治疗组与传统治疗组的中位无进展生存时间分别为28个月和11个月。结论:临床上首选治疗PCNSL的方案为大剂量甲氨喋呤化疗,与全脑放疗相结合进行治疗,具有一定的疗效,但不良反应较大,有很大可能会出现晚期神经毒性反应。大剂量甲氨喋呤联合利妥昔单克隆抗体治疗PCNSL,疗效较高,不良反应较少,副作用较小,在治疗老年PCNSL患者方面也具有更积极的价值。
[Abstract]:Objective: to evaluate the efficacy of high dose methotrexate combined with rituximab monoclonal antibody in the treatment of primary central nervous system lymphoma (PCNSL). Methods: 100 patients with primary central nervous system lymphoma were selected and divided into two groups: target therapy group and traditional treatment group. The target treatment group was treated with high dose methotrexate combined with rituximab monoclonal antibody, while the traditional treatment group was treated with high dose methotrexate combined with whole brain radiotherapy. The clinical data, imaging data, follow-up results and survival time of the two groups were compared and analyzed. Results: in the targeted treatment group, there were 33 cases of complete remission, 9 cases of stable condition, 5 cases of partial remission, 3 cases of progress, and 29 cases of complete remission in the traditional treatment group. There were 5 cases of stable condition, 11 cases of partial remission and 5 cases of progression. The median progression-free survival time was 28 months and 11 months in the target treatment group and the traditional treatment group, respectively. Conclusion: high dose methotrexate chemotherapy combined with whole brain radiotherapy is the first choice in clinical treatment of PCNSL. High dose methotrexate combined with rituximab monoclonal antibody in the treatment of PCNSLs has higher efficacy, less adverse reactions and less side effects. It also has more positive value in the treatment of elderly patients with PCNSL.
【作者单位】： 莱芜市人民医院肿瘤科;
【分类号】：R739.4
，
本文编号：2178381
[Abstract]:Objective: to evaluate the efficacy of high dose methotrexate combined with rituximab monoclonal antibody in the treatment of primary central nervous system lymphoma (PCNSL). Methods: 100 patients with primary central nervous system lymphoma were selected and divided into two groups: target therapy group and traditional treatment group. The target treatment group was treated with high dose methotrexate combined with rituximab monoclonal antibody, while the traditional treatment group was treated with high dose methotrexate combined with whole brain radiotherapy. The clinical data, imaging data, follow-up results and survival time of the two groups were compared and analyzed. Results: in the targeted treatment group, there were 33 cases of complete remission, 9 cases of stable condition, 5 cases of partial remission, 3 cases of progress, and 29 cases of complete remission in the traditional treatment group. There were 5 cases of stable condition, 11 cases of partial remission and 5 cases of progression. The median progression-free survival time was 28 months and 11 months in the target treatment group and the traditional treatment group, respectively. Conclusion: high dose methotrexate chemotherapy combined with whole brain radiotherapy is the first choice in clinical treatment of PCNSL. High dose methotrexate combined with rituximab monoclonal antibody in the treatment of PCNSLs has higher efficacy, less adverse reactions and less side effects. It also has more positive value in the treatment of elderly patients with PCNSL.
【作者单位】： 莱芜市人民医院肿瘤科;
【分类号】：R739.4
，
本文编号：2178381
本文链接：https://www.wllwen.com/yixuelunwen/shenjingyixue/2178381.html
最近更新
教材专著
